# JY232

Source: https://onco.cc/drugs/jy232/  
OnCo record `jy232` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

JY232 is an experimental in vivo CAR-T therapy from Genocury Biotech, in early studies for multiple myeloma.

## Summary

JY232 is an in vivo CAR-T (an infusion that makes CAR-T cells inside the body) from Genocury Biotech. The registry says it is designed to generate functional CAR-T cells directly within the body; it does not state which protein the CAR recognises. An investigator-initiated, single-centre early phase 1 study (NCT07336823), registered in January 2026, is recruiting. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Also known as: JY232 Injection
- Tags: pipeline; ctgov-ingest
- Code: JY232
- Modality: In vivo CAR-T (an infusion that makes CAR-T cells inside the body)
- Mechanism: The registry says it is designed to generate functional CAR-T cells directly within the body; it does not state which protein the CAR recognises.

## Sources

- ClinicalTrials.gov NCT07336823: https://clinicaltrials.gov/study/NCT07336823

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- companies: [Genocury Biotech](https://onco.cc/companies/genocury-biotech/)
- trials: [JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma](https://onco.cc/trials/nct07336823/)

---
JSON: https://onco.cc/api/v1/entities/jy232.json